Naropin Drug Interactions

Naropin should be used with caution in patients receiving other local anaesthetics or agents structurally related to amide-type local anaesthetics, e.g certain antiarrhythmics, such as lidocaine and mexiletine, since the systemic toxic effects are additive.
Specific interactions studies with ropivacaine and anti-arrhythmics class III (e.g. amiodarone) have not been performed but caution is advised (see also Precautions).
In healthy volunteers ropivacaine clearance was reduced by up to 77% during co-administration of fluvoxamine, a potent competitive inhibitor of CYP1A2. CYP1A2 is involved in the formation of 3-hydroxy-ropivacaine, a major metabolite. Thus strong inhibitors of CYP1A2, such as fluvoxamine and enoxacin, given concomitantly with Naropin can cause a metabolic interaction leading to an increased ropivacaine plasma concentration. Prolonged administration of ropivacaine should therefore be avoided in patients treated with strong inhibitors of CYP1A2, (see also Precautions).